Stockwinners Market Radar for February 26, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:01 EST Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Amazon (AMZN) is expanding ultrafast delivery options, a sign that it remains committed to pushing its logistics system for speed as it scales back plans in other areas, The Wall Street Journal's Sebastian Herrera reports. The expansions are happening at a crucial point for Amazon, which faces competition for fast-delivery options while Chief Executive Officer Andy Jassy puts a renewed focus on profits, the author notes. 2. Microsoft (MSFT) has unveiled previews of two AI-powered services designed to manage telecom networks, drawing on the same capabilities used to manage the tech giant's Azure cloud platform, Reuters' Supantha Mukherjee and Martin Coulter report. Operators can benefit from advanced artificial intelligence that helps to unlock new business opportunities from data on and insights into their operations -- including the rollout of high-speed 5G networks -- the company said. Telecom partners such as AT&T (T), Ericsson (ERIC), and Nokia (NOK) will be able to benefit from Microsoft's new Nexus service, an all-in-one platform allowing operators to manage their networks from the cloud, and two different "AIOps" services. 3. A boom in clean-energy manufacturing is fast getting under way across the U.S., but despite the dollars flooding in, it remains difficult to invest profitably in clean-energy companies, Avi Salzman writes in this week's edition of Barron's. To find stocks that can rise despite those pressures, it's worth considering names that have found true niches or have a head start in specific areas. These include Corning (GLW), Enphase Energy (ENPH), Neste (NTOIY), Schneider Electric (SBGSY), and Freyr Battery (FREY), the author adds. 4. Disney's (DIS) "Ant-Man and the Wasp: Quantomania" stayed atop the domestic box office with an estimated $32.2M but fell 69.7% in North America. This was the worst decline ever for a Marvel Cinematic Universe title following "Black Window" with 67.8%, which opened during the pandemic and was made available simultaneously in the home. "Ant-Man 3" also suffered the worst second-weekend drop of any superhero movie that had opened to $100M or more. Overseas, the pic grossed another $46.4M for a global cume of $363.6M. 5. FirstEnergy (FE) and British American Tobbaco (BTI) saw positive mentions in this week's edition of Barron's.

16:43 EST Blueprint Medicines presents registrational data from PIONEER trial AYVAKIT - Blueprint Medicines announced detailed results from the PIONEER trial of AYVAKIT in patients with indolent systemic mastocytosis. As previously reported, AYVAKIT achieved statistically significant and clinically meaningful improvements on the primary and all key secondary endpoints. New results further highlight the benefits of AYVAKIT on pathological mast cell burden, disease symptoms - including total symptom score, most severe symptom and all individual symptoms - and quality of life. Across clinical measures, improvements continued to deepen over time in patients treated with AYVAKIT through 48 weeks. AYVAKIT was well-tolerated with a safety profile favorable to placebo, and 96 percent of patients in the AYVAKIT arm opted to continue treatment in the open-label extension study. Based on these data, Blueprint Medicines submitted a supplemental new drug application for AYVAKIT to the U.S. Food and Drug Administration and a type II variation marketing authorization application for AYVAKYT to the European Medicines Agency for the treatment of patients with indolent SM. The FDA has granted priority review to the sNDA for AYVAKIT with a Prescription Drug User Fee Act action date of May 22, 2023, and the EMA has validated the MAA for AYVAKYT.